What’s the news: The U.S. Food and Drug Administration (FDA) has cautioned against the use of some medicines FDA-approved to treat or prevent malaria and being used for the treatment or prevention of COVID-19. The FDA has warned that hydroxychloroquine and chloroquine should only be used in hospitals or clinical trials because they have been linked to a risk of heart rhythm problems, especially when paired with the antibiotic azithromycin.
Why it’s important: There have been reports of serious, potentially life-threatening, heart rhythm problems in patients with COVID-19 who are treated with hydroxychloroquine or chloroquine and used in combination with azithromycin and other QT prolonging medicines.
“We are also aware of increased use of these medicines through outpatient prescriptions. Therefore, we would like to remind health care professionals and patients of the known risks associated with both hydroxychloroquine and chloroquine,” says the FDA drug safety communication.
There is no evidence to show that hydroxychloroquine and chloroquine—prescribed for years to treat lupus and arthritis—are safe and effective for treating or preventing COVID-19. These medicines are currently being studied in clinical trials for COVID-19 treatment and prophylaxis. However, in late March the FDA issued an emergency use authorization (EUA) to supply chloroquine and hydroxychloroquine from the Strategic National Stockpile to treat certain patients who are hospitalized with COVID-19 and for whom clinical trials are not available, or participation is not feasible. Learn more about lessons learned from COVID-19, including how treatment is unclear at this time.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Hydroxychloroquine and chloroquine can cause abnormal heart rhythms such as QT interval prolongation and ventricular tachycardia. Risks may increase when combined with other medicines known to prolong the QT interval, including the antibiotic azithromycin, which is also being used in some patients with COVID-19 without FDA approval for this use. When patients have other underlying health issues such as heart disease or kidney disease, they are placed at an increased risk when receiving these medicines.
When used for COVID-19, hydroxychloroquine and chloroquine should be limited to clinical trial settings to decrease the risk of associated heart problems and other adverse events.
Source: AMA
